A Look At Intellia Therapeutics (NTLA) Valuation After Its Recent Share Price Rebound [Yahoo! Finance]
Intellia Therapeutics (NTLA) was upgraded by JonesTrading from "hold" to "buy". They now have a $29.00 price target on the stock.
Intellia Therapeutics (NTLA) had its price target lowered by Canaccord Genuity Group Inc. from $54.00 to $48.00. They now have a "buy" rating on the stock.
Intellia Therapeutics (NTLA) had its "buy" rating reaffirmed by Brookline Capital Acquisition Corp..
Intellia Therapeutics (NTLA) had its price target raised by Leerink Partners from $27.00 to $29.00. They now have an "outperform" rating on the stock.